Integrated Motor-Cognitive Training in Parkinson's Disease: A Feasibility Study (P_Feasibility)
Parkinson's disease is a progressive neurodegenerative condition characterized by both motor symptoms (such as bradykinesia, rigidity, tremor, and postural instability) and non-motor symptoms, including cognitive impairments (affecting working memory, executive functions, and attention). Combined interventions that target both domains simultaneously or consecutively have shown potential to produce superior benefits compared to isolated motor or cognitive training.
The purpose of this study is to evaluate the feasibility, adherence, and preliminary clinical results of efficacy of an integrated and combined motor-cognitive rehabilitation training in patients diagnosed with Parkinson's disease.
This feasibility study will enroll 12 participants with Parkinson's disease. All participants will undergo a comprehensive 10-session integrated rehabilitation program combining digital cognitive individual stimulation and group functional motor training. The primary focus is to assess acceptability, safety, and adherence to this combined approach, while secondary outcomes will observe changes in relevant cognitive and motor clinical variables.
調査の概要
状態
条件
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Sofia Straudi, MD, PhD
- 電話番号:+390532238720
- メール:sofia.straudi@unife.it
研究場所
-
-
FE
-
Ferrara、FE、イタリア、44124
- 募集
- Ferrara University Hospital
-
コンタクト:
- Sofia Straudi, MD, PhD
- 電話番号:0532238720
- メール:sofia.straudi@unife.it
-
副調査官:
- Gaia Palma, PhD student, Psychologist
-
副調査官:
- Andrea Baroni, Physiotherapist, PhD
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Diagnosis of Parkinson's disease
- Presence of motor symptoms attributable to Parkinson's disease
- Availability to participate in both treatments (cognitive and motor)
- Severity of symptoms compatible with participation in group physical therapy
- Absence of other medical conditions that could interfere with treatment delivery
- Montreal Cognitive Assessment (MoCA) score >= 18
- Consent to participate in group-based motor training
- Absence of falls in the 3 months prior to baseline evaluation
Exclusion Criteria:
- Concomitant major neurological or psychiatric disorders
- Severe cardio-pulmonary, renal, or hepatic diseases
- Changes in baseline pharmacological therapy within 3 months prior to enrollment
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Combined Motor-Cognitive Training Group
Participants will receive a 10-session integrated rehabilitation program combining individual digital cognitive stimulation and group functional motor training |
Participants complete a 10-session motor-cognitive training program (3 times per week). Interventions occur on the same day in groups of 3, supervised by a neuropsychologist and physiotherapist.
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Feasibility Outcomes: Eligibility Rate
時間枠:Baseline
|
Calculated as the ratio of eligible patients to the total number of screened patients. |
Baseline
|
|
Feasibility Outcomes: Recruitment Rate
時間枠:Baseline
|
Calculated as the ratio of recruited patients to total eligible patients. |
Baseline
|
|
Feasibility Outcomes: Monthly Recruitment Rate
時間枠:Baseline
|
Defined as the average number of participants enrolled per month. |
Baseline
|
|
Feasibility Outcomes: Drop-out Rate
時間枠:score changes after intervention (4 weeks, T1)
|
The percentage of participants who withdraw from the study. |
score changes after intervention (4 weeks, T1)
|
|
Feasibility Outcomes: Adherence Rate
時間枠:score changes after intervention (4 weeks, T1)
|
The percentage of scheduled training sessions attended |
score changes after intervention (4 weeks, T1)
|
|
Feasibility Outcomes: Longitudinal Retention Rate
時間枠:Post-intervention follow-up assessment (3 months after intervention completion)
|
The percentage of enrolled participants who complete all follow-up assessments |
Post-intervention follow-up assessment (3 months after intervention completion)
|
|
Feasibility Outcomes: Self-Reported Acceptability
時間枠:score changes after intervention (4 weeks, T1)
|
Participants will complete a questionnaire at the end of the intervention to evaluate their subjective experience, perceived benefits, and difficulties of the treatment. Items are rated on a 5-point Likert scale ranging from 1 ("low") to 5 ("extremely high"), with higher scores indicating a more positive evaluation or greater perceived benefit/difficulty. |
score changes after intervention (4 weeks, T1)
|
|
Feasibility Outcomes: Adverse Events
時間枠:score changes after intervention (4 weeks, T1)
|
The incidence and severity of any adverse events (e.g., falls or excessive fatigue) recorded during the study. |
score changes after intervention (4 weeks, T1)
|
|
Feasibility Outcomes: Motor Exercise Intensity
時間枠:Monitored during every training session (Up to 4 weeks, from Sessions 1 through 10)
|
The Borg Rating of Perceived Exertion (RPE) will be used to monitor and quantify physical and cognitive effort. Total score ranges from 6 to 20. Higher scores indicate greater perceived exertion |
Monitored during every training session (Up to 4 weeks, from Sessions 1 through 10)
|
|
Feasibility Outcomes: Motor Exercise Exertion
時間枠:Monitored during every training session (Up to 4 weeks, from Sessions 1 through 10)
|
The Borg Intensity Scale-Exerciser (BIS-E) will be used to quantify exertion. Total score ranges from 0 to 30, higher scores indicate greater perceived balance effort, difficulty, and postural instability during circuit stations. |
Monitored during every training session (Up to 4 weeks, from Sessions 1 through 10)
|
|
Feasibility Outcomes: Digital Cognitive Progression Index (NeuronUP Activity Score)
時間枠:Monitored during every training session (Up to 4 weeks, from Sessions 1 through 10)
|
Digital Cognitive Progression Index (NeuronUP Activity Score) will be used to quantifies session-by-session cognitive performance and adaptive difficulty progression across the 10 training sessions. The score is calculated using NeuronUP's standardized algorithm based on accuracy, total completed phases, and maximum difficulty reached, yielding a score from 0 to 100. Higher scores reflect greater task proficiency and successful progression to higher difficulty levels. This metric serves as an exploratory/feasibility measure of intra-intervention cognitive learning. |
Monitored during every training session (Up to 4 weeks, from Sessions 1 through 10)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Motor Outcomes: Change in dynamic balance, mobility, and gait
時間枠:Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
The Timed Up and Go Test (TUG Single Task) will be used to assess the change in dynamic balance, mobility, and gait. Evaluated as time (in seconds). Lower time indicates better functional mobility. |
Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
|
Motor Outcomes: Change in Gait speed
時間枠:Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
10-Meter Walk Test (10MWT) will be used to assess change in gait speed over a 10-meter distance. Evaluated as speed in meters per second (m/s). Higher values indicate faster walking speed and improved gait dynamics. |
Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
|
Motor Outcomes: Change in Distance Walked
時間枠:Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
The 6-Minute Walk Test (6MWT) will be used to assess change in total distance walked (in meters) within 6 minutes. Evaluated as total distance walked (in meters) within 6 minutes. Higher distance indicates superior physical endurance. |
Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
|
Motor Outcomes: Change in Dynamic Balance
時間枠:Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
Mini-BESTest Total Score will be used to assess change dynamic balance abilities across four subscales (anticipatory postural adjustments, reactive postural control, sensory orientation, and dynamic gait).Total score ranges from 0 to 28, with higher scores indicating superior dynamic balance and lower fall risk. |
Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
|
Motor Outcomes: Change in Finger motor speed
時間枠:Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
The Finger Tapping Test Performance will be used to assess motor speed. Measures include total number of taps (right and left hand). Higher tap counts indicate better motor control. |
Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
|
Cognitive Outcomes: Change in Global cognitive function
時間枠:Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
The Montreal Cognitive Assessment (MoCA) total score will be used to assess global cognitive function. The scale ranges from 0 to 30, with higher scores indicating better global cognitive function (a score of 26 or above is generally considered normal). |
Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
|
Cognitive Outcomes: Change in Visual search and processing speed
時間枠:Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
The Trail Making Test Part A (TMT-A) will be used to assess visual search abilities and processing speed. |
Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
|
Cognitive Outcomes: Change in executive function, cognitive flexibility, and set-shifting.
時間枠:Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
The Trail Making Test Part B (TMT-B) Time will be used to assess executive function, cognitive flexibility, and set-shifting. |
Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
|
Cognitive Outcomes: Change in Information processing speed and attention
時間枠:Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
The Symbol Digit Modalities Test (SDMT) will be used to assess information processing speed and attention. |
Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
|
Cognitive Outcomes: Decision-making processing speed and cognitive-motor control
時間枠:Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
The Choice Reaction Time (CRT) Task will be used to assess decision-making processing speed and cognitive-motor control. Evaluated via number of correct responses, mean reaction time (in milliseconds) for correct responses, and mean reaction time for error responses. Lower reaction times and higher correct rates indicate better performance. |
Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
|
Cognitive Outcomes: Change in perceptive-motor speed
時間枠:Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
The Simple Reaction Time (SRT) will be used to assess reaction time speed. Evaluated as mean reaction time (in milliseconds) for correct responses and number of correct responses. Lower reaction times indicate faster processing speed; Higher correct responses indicate better accuracy. |
Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
|
Change in Quality of Life
時間枠:Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
The EQ-5D Quality of Life Questionnaire will be used to assess health-related quality of life across 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). Higher scores indicate superior quality of life. |
Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
|
Change in Fatigue
時間枠:Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
The Parkinson Fatigue Scale (PFS-16) will be used to assess the impact of fatigue specific to Parkinson's disease. Total mean score ranges from 1 to 5. Higher scores indicate greater perceived fatigue. |
Baseline (T0), post-treatment (4 weeks, T1), and follow-up (T2, 3 months post-treatment)
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- 710/2025/Oss/AOUFe
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。